ENXTBR:ARGXBiotechs
How FDA Priority Review For VYVGART’s Seronegative gMG Use At argenx (ENXTBR:ARGX) Has Changed Its Investment Story
In January, argenx reported continued momentum for its autoimmune drug VYVGART, as the US FDA accepted a priority review of a supplemental biologics license application to extend its use to adults with acetylcholine receptor antibody‑seronegative generalized myasthenia gravis, while the franchise continued to post strong global sales growth in 2025.
This combination of regulatory progress and broader clinical ambitions, spanning indications like immune thrombocytopenia, myositis and...